首页> 外文期刊>Annals of clinical biochemistry. >Clinical value of CTLA4-associated microRNAs combined with inflammatory factors in the diagnosis of non-small cell lung cancer
【24h】

Clinical value of CTLA4-associated microRNAs combined with inflammatory factors in the diagnosis of non-small cell lung cancer

机译:CTLA4相关的MicroRNA的临床价值联合炎症因子在非小细胞肺癌诊断中

获取原文
获取原文并翻译 | 示例
           

摘要

Background The current study aimed to explore the value of cytotoxic T-lymphocyte-associated protein 4 (CTLA4)-associated microRNAs combined with inflammatory factors in the differential diagnosis of non-small cell lung cancer (NSCLC). Methods A retrospective study including 245 NSCLC patients and 245 healthy controls was conducted on a testing group. A regression formula for NSCLC prediction was established based on the testing group. Two validation groups from two centres were used to assess the novel logistic regression model including 144 NSCLC patients and 144 healthy controls recruited from the Wuchang Hospital Affiliated to Wuhan University of Science and Technology, and 128 NSCLC patients and 128 healthy controls recruited from the Zhongnan Hospital of Wuhan University. Results Predictive software and dual-luciferase reporter assays showed that miR-155-5p and miR-630 could target CTLA4 expression. The miR-155-5p and miR-630 concentrations in the NSCLC patients were significantly lower, and the neutrophil to lymphocyte ratio, hypersensitive C-reactive protein (hs-CRP), interleukin 6, cytokeratin-19-fragment (CYFRA21-1), squamous cell carcinoma antigen (SCCA) concentrations and the smoking rate were significantly higher than that in healthy controls (P < 0.05). A logistic regression model that included smoking, neutrophil to lymphocyte ratio, hs-CRP, interleukin 6, CYFRA21-1, SCCA, miR-155-5p and miR-630 was performed. This model presented a high discriminating value (AUC: 0.830, sensitivity/specificity: 74.6%/89.7%) than any single indicator. In the validation groups, this model still showed a high discriminating value (AUC = 0.838 with the internal validation group; AUC = 0.851 with the external validation group). Conclusion The current model has potential significance for the non-invasive diagnosis for NSCLC.
机译:背景技术目前的研究旨在探讨细胞毒性T淋巴细胞相关蛋白4(CTLA4) - 分配的MicroRNA的价值,所述MicroRNA联合非小细胞肺癌(NSCLC)的鉴别诊断中的炎症因子。方法对试验组进行包括245例NSCLC患者和245名健康对照的回顾性研究。基于测试组建立了NSCLC预测的回归公式。两个中心的两个验证组用于评估新的逻辑回归模型,包括从武汉科学技术大学武昌医院招募的144名NSCLC患者和144名健康对照,并从中南医院招募了128名NSCLC患者和128名健康控制作者:王莹,武汉大学学报JOURNAL。结果预测性软件和双荧光素报道器测定结果显示miR-155-5p和miR-630可以靶向CTLA4表达。 NSCLC患者的miR-155-5p和miR-630浓度显着降低,中性粒细胞与淋巴细胞比,过敏性C反应蛋白(HS-CRP),白细胞介素6,细胞角蛋白-19-片段(Cyfra21-1) ,鳞状细胞癌抗原(SCCA)浓度和吸烟率明显高于健康对照(P <0.05)。进行了含有吸烟,嗜中性粒细胞比,HS-CRP,白细胞介素6,CYFRA21-1,SCCA,MIR-155-5P和MIR-630的逻辑回归模型。该模型呈现出高分辨率值(AUC:0.830,敏感性/特异性:74.6%/ 89.7%)而不是任何单一指标。在验证组中,此模型仍显示出高分辨率值(AUC = 0.838,内部验证组; AUC = 0.851,外部验证组)。结论目前模型对NSCLC的非侵入性诊断具有潜在意义。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号